Drugs /

ulixertinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.

Clinical Trials

View Clinical Trials for ulixertinib

Ulixertinib has been investigated in 6 clinical trials, of which 4 are open and 2 are closed. Of the trials investigating ulixertinib, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open).

BRAF Mutation, HRAS Mutation, and KRAS Mutation are the most frequent biomarker inclusion criteria for ulixertinib clinical trials.

Malignant solid tumor, acute myeloid leukemia, and cholangiocarcinoma are the most common diseases being investigated in ulixertinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ulixertinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ulixertinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ulixertinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
1h-pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-n-((1s)-1-(3-chlorophenyl)-2-hydroxyethyl)-, vrt752271, erk inhibitor bvd-523, bvd-523, ulixertinib
Drug Categories [2]:
ERK inhibitor, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
MAPK1, MAPK3
NCIT ID [1]:
C104744

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.